Anavex Life Sciences (AVXL) Cash & Equivalents Growth (5y) (2015 - 2025)
Anavex Life Sciences (AVXL) Cash & Equivalents Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.71% |
| Sep 30, 2025 | 28.53% |
| Jun 30, 2025 | 29.65% |
| Mar 31, 2025 | 34.23% |
| Dec 31, 2024 | 34.48% |
| Sep 30, 2024 | 42.90% |
| Jun 30, 2024 | 45.54% |
| Mar 31, 2024 | 48.26% |
| Dec 31, 2023 | 47.32% |
| Sep 30, 2023 | 45.79% |
| Jun 30, 2023 | 43.07% |
| Mar 31, 2023 | 43.01% |
| Dec 31, 2022 | 38.63% |
| Sep 30, 2022 | 40.30% |
| Jun 30, 2022 | 43.94% |
| Mar 31, 2022 | 45.70% |
| Dec 31, 2021 | 48.17% |
| Sep 30, 2021 | 75.31% |
| Jun 30, 2021 | 74.54% |
| Sep 30, 2020 | 13.85% |